Business / Finance

RSS

Cambrex sales increase by 5.7% in first quarter 2013

Cambrex Corporation reports results for the first quarter ended March 31, 2013.

3 May 2013

BioLife Solutions licenses specific areas of intellectual property to Janssen

BioLife Solutions, Inc., a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer, today announced that it has licensed specific areas of its intellectual property to Janssen Research & Development, LLC.

2 May 2013

RainDance Technologies announces closing of $20M Series E financing round

RainDance Technologies, Inc., the Digital Biology Company, today announced the closing of a $20 million Series E financing round. The company also announced that Myriad Genetics, Inc. has joined as a new strategic equity investor.

29 Apr 2013

Opsona raises €33M in oversubscribed financing round

Opsona Therapeutics Limited, the innate immune drug development company, today announced that it has raised €33 million (US $ 43 million) in an oversubscribed Series C financing.

29 Apr 2013

Shin Poong to develop, market Almac Discovery's ALM201 in South Korea

Almac Discovery today announced the licensing of its novel anti-angiogenic peptide ALM201 to Shin Poong Pharmaceutical Company Ltd for clinical development and marketing in South Korea.

29 Apr 2013

Simulations Plus to distribute quarterly cash dividend in May 2013

Simulations Plus, Inc., a leading provider of simulation and modeling software for pharmaceutical discovery and development, today announced that its Board of Directors has decided to distribute a cash dividend in May.

26 Apr 2013

HMS Holdings revenue increases 8.7% to $116.6M in first quarter 2013

HMS Holdings Corp. today announced financial results for its first quarter ended March 31, 2013 and provided revised 2013 guidance.

26 Apr 2013

Sectra signs agreement to distribute healthcare IT suite in Puerto Rico

International medical imaging IT company, Sectra announces an exclusive agreement with Answer Medical Solutions to distribute its healthcare IT suite throughout Puerto Rico.

26 Apr 2013

DJO Global reports first quarter results for 2013

DJO Global, Inc., a leading global provider of medical device solutions for musculoskeletal health, vascular health and pain management, today announced financial results for its public reporting subsidiary, DJO Finance LLC ("DJOFL"), for the first quarter ended March 30, 2013.

26 Apr 2013

Scioderm completes Series A financing commitment totaling $16 million

Scioderm, a company developing novel dermatology therapeutics, today announced the completion of a Series A financing commitment totaling $16 million. Morgenthaler Ventures led the Series A financing, with Technology Partners as the second investor participating in the round.

26 Apr 2013

Lifepoint Hospitals’ revenues increase 9.4% to $931.1 million in first quarter 2013

LifePoint Hospitals, Inc. today announced results for the first quarter ended March 31, 2013. For the first quarter ended March 31, 2013, revenues from continuing operations were $931.1 million, up 9.4% from $851.0 million for the same period a year ago.

26 Apr 2013

Covidien net sales increase 5% to $3.10 billion in second quarter 2013

Covidien plc today reported results for the second quarter of fiscal 2013 (January - March 2013). Second-quarter net sales of $3.10 billion increased 5% from the $2.95 billion reported in the second quarter a year ago. Foreign exchange rate movement lowered the quarterly sales growth rate by two percentage points.

26 Apr 2013

New Haven Pharmaceuticals gets venture loan facility from Horizon Technology Finance

Horizon Technology Finance Corporation ("Horizon"), a leading specialty finance company that provides secured loans to venture capital and private equity backed development-stage companies in the technology, life science, healthcare information and services, and clean-tech industries, today announced it has closed a $2 million venture loan facility with New Haven Pharmaceuticals, Inc. ("NHP"), a developer of prescription pharmaceuticals that utilize currently marketed drugs or active pharmaceutical ingredients generally recognized as safe for use in therapeutic applications.

26 Apr 2013

Immudex signs agreement to provide MHC-peptide multimer and Elispot proficiency panel services

Immudex has entered into a strategic agreement with the US Cancer Immunotherapy Consortium (CIC) of the Cancer Research Institute, and the European Association for Cancer Immunotherapy (CIMT), under which Immudex will provide MHC-peptide multimer and Elispot proficiency panel services worldwide.

26 Apr 2013

Universal Health Services net revenues increase 2% to $1.83 billion in first quarter 2013

Universal Health Services, Inc. announced today that its reported net income attributable to UHS was $119.8 million, or $1.21 per diluted share, during the first quarter of 2013 as compared to $128.6 million, or $1.31 per diluted share, during the comparable quarter of 2012.

26 Apr 2013

Molina Healthcare reports strong quarterly results for 2013

Molina Healthcare, Inc. today reported its financial results for the quarter ended March 31, 2013.

26 Apr 2013

Dyax reports Q1 2013 financial results; LFRP portfolio continues to be a growth driver

Dyax Corp. today announced financial results for the first quarter ended March 31, 2013. The Company will host a webcast and conference call at 5:00 p.m. (ET) today to review financial results and updates regarding its key value drivers - the KALBITOR® (ecallantide) business, the broader angioedema portfolio and the Licensing and Funded Research Program (LFRP).

26 Apr 2013

Rochester Medical's net sales increase 8% to $16,635,000 in second quarter 2013

Rochester Medical Corporation today announced operating results for its second quarter ended March 31, 2013. The Company reported sales of $16,635,000 for the current quarter compared to $15,427,000 for the second quarter of last year. The Company also reported net income of $1,199,000 or $0.10 per diluted share compared to $603,000 or $0.05 per diluted share for the same period last year.

26 Apr 2013

Cempra reports net loss of $10.3 million in first quarter 2013

Cempra, Inc., a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today reported financial results for the first quarter ended March 31, 2013.

26 Apr 2013

Greatbatch reports 19% increase in adjusted diluted EPS targets for first quarter 2013

Greatbatch, Inc., today announced results for its first quarter ended March 29, 2013 highlighted by a 19% increase in adjusted diluted EPS despite negative 4% constant currency organic revenue growth.

26 Apr 2013